Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05210283 · ClinicalTrials.gov registry record
CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer
A clinical trial of Colorectal Cancer, sponsored by Exact Sciences Corporation.
- Active
- Registry status
- 1,017
- Enrollment target
- 20
- Study locations
NCT05210283: Active study of Colorectal Cancer, sponsored by Exact Sciences Corporation.
NCT05210283 is a study of Colorectal Cancer that is active but no longer recruiting, run by Exact Sciences Corporation. The registered enrollment target is 1,017 participants, below the 1,508-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (33% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05210283, a study of Colorectal Cancer, is active but no longer recruiting, sponsored by Exact Sciences Corporation.
- ACTIVE NOT RECRUITING
- Registry status
- 1,017 participants
- Enrollment target
- 20
- Study locations
Study Summary
The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up to two years of clinical (passive) follow up.
Conditions Studied
Interventions
- DEVICE MRD
Study Locations (20)
Florida
- University of Florida Division of Hematology & Oncology - Gainesville
- Mount Sinai Medical - Comprehensive Cancer Center - Miami Beach
- Mid Florida Cancer Centers - Orange City
Maryland
- MedStar Georgetown Cancer Institute at MedStar Georgetown University Hospital - Baltimore
- Meritus Center for Clinical Research - Hagerstown
- University of Maryland St. Joseph Medical Center - Towson
North Carolina
- Atrium Health Levine Cancer Institute - Charlotte
- FirstHealth Outpatient Cancer Center - Pinehurst
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
California
- Facey Medical Group - Mission Hills - Endoscopy Center & Gastroenterology - Mission Hills
- Torrance Memorial Hunt Cancer Institute - Torrance
Illinois
- Edward Cancer Center - Elmhurst
- Illinois Cancer Care - Peoria
Iowa
- Mercy Medical Center - Cedar Rapids
Kansas
- University of Kansas Cancer Center - Westwood
Minnesota
- Metro Minnesota Community Oncology Consortium (MMCORC) - Saint Louis Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,017 participants |
| Start Date | 2021-12-15 |
| Est. Completion | 2027-05-15 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05210283
The ClinicalTrials.gov registry entry for NCT05210283 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,017 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,508-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (33% lower). The listed sponsor is Exact Sciences Corporation, which has 30 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which MRD is the first listed.
NCT05210283 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Maryland, North Carolina.
Frequently Asked Questions
What is clinical trial NCT05210283 about?
NCT05210283 is a clinical study titled "CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer". The CORRECT - MRD II study will prospectively enroll patients who have undergone complete surgical resection for stage II or III colorectal cancer. Maximum duration of participant participation is up to seven years from enrollment to study completion with up to five years of active follow up and up ...
What is the current status of trial NCT05210283?
This trial is currently active not recruiting. The enrollment target is 1,017 participants. The study started on 2021-12-15. Estimated completion is 2027-05-15.
What conditions does trial NCT05210283 study?
This clinical trial studies the following conditions: Colorectal Cancer.
What interventions are being tested in trial NCT05210283?
The interventions under investigation include: MRD (DEVICE).
Who is sponsoring clinical trial NCT05210283?
This trial is sponsored by Exact Sciences Corporation, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05210283 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Cross-sectional Partnership to Improve Prevention and Health Equity Among African Americans
RECRUITING · NA
-
Precise Oncology Interventions in Nutrition and Training (OnPoint)
RECRUITING · NA
-
Resistance Exercise and Creatine in Colorectal Cancer
RECRUITING · NA
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
RECRUITING
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.